Product category:
Clinical chemistry analysis
News Release from: Inverness Medical Innovations | Subject: BinaxNow Malaria
Edited by the Laboratorytalk Editorial
Team on 11 December 2007
Rapid diagnostic for malaria is now FDA
cleared
BinaxNow Malaria detects Plasmodium falciparum, P vivax, P malariae and P ovale antigens in whole blood in as little as 15 minutes, for field or laboratory use with its easy-to-use test card forma
Inverness Medical's BinaxNow Malaria for the rapid diagnosis of malaria infection is the only rapid test for malaria cleared by the FDA As a result, BinaxNow can ensure the most appropriate treatment is administered before protracted laboratory tests are complete, helping to prevent the occurrence of unnecessary complications
This article was originally published on Laboratorytalk on 8 Jul 2008 at 8.00am (UK)
Related stories
Detect C difficile infection in under 30 minutes
Clostridium difficile is responsible for the most common form of hospital-acquired diarrhoea, affecting over 500,000 people in the USA and one out of every 1000 patients hospitalised in Europe
Rapid detection of cryptosporidium with Techlab
In UK news this week, the water borne parasite Cryptosporidium has been found in the local water supply of the Northampton and Daventry area, affecting approximately 250,000 people
Malaria is a parasitic disease transmitted from person to person via a mosquito vector and can cause severe fever, chills and flu like symptoms.
With approximately 40% of the world's population at risk of malaria, early diagnosis and effective treatment are crucial to controlling this potentially fatal disease.
BinaxNow is ideal for differing diagnostic needs within malaria endemic regions and malaria-free countries.
Since malaria is prevalent in many of the world's holiday hotspots, travellers from malaria-free countries are highly susceptible to infection due to little or no immunity and can be wrongly diagnosed on their return home.
With limited experience in diagnosing tropical diseases not prevalent in their own countries, clinicians can have added confidence in the comprehensible visual result provided by BinaxNow Malaria.
For this reason BinaxNow Malaria is the first and only rapid test to be used alongside standard laboratory testing cleared by the FDA for the detection of malaria.
With the majority of those at risk of malaria living in the poorest countries in the world, in areas lacking reliable electricity and diagnostic equipment, BinaxNow Malaria also enables initial rapid testing to occur in remote clinics.
This would help to prevent the rapid spread of antimalarial drug resistance, as treatment can be made more targeted and controlled.
• Inverness Medical Innovations: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
